- Home
- SONM vs AYTU Comparison
SONM vs AYTU Comparison
Compare SONM & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONM | AYTU |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 27.4M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SONM | AYTU |
|---|---|---|
| Price | $3.46 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 8.2K | ★ 21.0K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $58,298,000.00 | $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $0.76 | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.58 | $1.65 |
| 52 Week High | $12.30 | $3.07 |
Technical Indicators
Market Signals| Indicator | SONM | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 35.83 |
| Support Level | $2.86 | N/A |
| Resistance Level | $4.37 | $2.33 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 32.74 | 26.00 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.